Syros Pharmaceuticals (SYRS) Tops Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Syros Reports Second Quarter 2021 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
August 5, 2021 7:30 AM EDTToday Announced Agreement with Roche to Evaluate SY-5609 in Combination with Immunotherapy in BRAF-Mutant Colorectal Cancer Patients
Additional Dose Escalation Data for SY-5609 to be Highlighted in Oral Presentation at ESMO Congress; On Track to Advance into Phase 1 Expansion in 2H 2021
On Track to Initiate SELECT-AML-1 Randomized Phase 2 Trial of Tamibarotene in AML and Dose Confirmation Study for SY-2101 in APL in 2H 2021
Management to Host Conference Call at 8:30 a.m. ET Today
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals... More
